Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...
Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...
35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...
"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...
GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.
GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...
GSK will buy Canadian biotech 35Pharma for $950 million to gain HS235, a promising pulmonary hypertension treatment, ...
GSK plc (NSE: GSK) on Wednesday agreed to acquire 35Pharma Inc. for $950 million. 35Pharma is a Canada-based, private, ...
Pharma giant GSK is launching a five-year collaboration with The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) to advance human cellular models of neurodegenerative ...
The 35Pharma acquisition comes as GSK looks to stock up its pipeline amid the looming patent expiries soon to impact its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results